Related Experiment Video

Updated: Dec 7, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.4K

Sustained response to erlotinib and rapamycin in a patient with pediatric anaplastic oligodendroglioma

Laura C Geben1,2, Bret C Mobley3,4, Asa A Brockman1

  • 1Department of Cell & Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.

Pediatric Blood & Cancer
|October 1, 2020
PubMed

Insights

Genomic testing identified targeted therapies for a pediatric brain tumor. This precision medicine approach led to a sustained 33-month response in a patient with anaplastic oligodendroglioma.

Area of Science:

  • Oncology
  • Genomics
  • Precision Medicine

Background:

  • Precision medicine aims to tailor cancer treatments based on individual tumor mutations.
  • Pediatric anaplastic oligodendroglioma often presents challenges with standard treatment protocols.

Observation:

  • Genomic testing was employed to guide treatment selection for a refractory pediatric anaplastic oligodendroglioma.
  • Immunohistochemical analysis revealed abnormal signaling pathways and tumor cell heterogeneity.

Findings:

  • A targeted therapy regimen of erlotinib and rapamycin was administered based on genomic findings.
  • The patient achieved a 33-month sustained response to the targeted treatment.

Implications:

  • This case demonstrates the potential of genomic testing in selecting effective targeted therapies for rare pediatric cancers.
  • Understanding tumor signaling heterogeneity is crucial for developing future precision oncology strategies.
Keywords:
EGFRbrain tumormTORneuro-oncologypediatric oncologytargeted therapy

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.9K